Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07088978

Adaptation of the PROFFIT Instrument Into Turkish: A Validity and Reliability Study

The aim of this study is to evaluate the Turkish validity and reliability of the Patient Reported Outcomes for Fighting Financial Toxicity of Cancer (PROFFIT) developed in Italy.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

The scale validity of the study will be evaluated through language and content validity, construct validity, criterion validity, and known-group validity methods; while the scale reliability will be assessed by calculating the Cronbach's alpha and McDonald's omega reliability coefficients.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Individuals diagnosed with solid cancer or hematologic malignancy, either histologically or cytologically, and aware of their diagnosis,
  • Those who have received cancer treatment (chemotherapy, targeted therapy, immunotherapy, hormonal therapy, radiotherapy, or a combination of these treatments) within the last three months,
  • Individuals over the age of 18,
  • Those without a diagnosed psychiatric illness (such as depression, panic attacks, schizophrenia, etc.),
  • Individuals without auditory or cognitive impairments,
  • Turkish-speaking and literate volunteers.

Exclusion criteria

  • Individuals who fill out the data collection forms incompletely or wish to withdraw from the study.

Treatment and study plan

Primary outcomes

  1. Validity Assessment-Language and Content Validity

    Time frame: Through study completion, an average of 12 months

    Language and Content Validity: To assess the relevance and appropriateness of the translated items, a panel of at least six experts in oncology, psychology, and instrument development will evaluate each item.

  2. Validity Assessment-Content Validity Index (CVI)

    Time frame: Through study completion, an average of 12 months

    Content Validity Index (CVI) will be calculated based on expert ratings to determine the proportion of items deemed relevant.

  3. Validity Assessment-Content Validity Ratio (CVR)

    Time frame: Through study completion, an average of 12 months

    Content Validity Ratio (CVR) will be used to assess whether each item is essential for measuring the construct.

  4. Validity Assessment-Construct Validity

    Time frame: Through study completion, an average of 12 months

    Confirmatory Factor Analysis (CFA) will be performed to verify whether the factor structure of the Turkish version aligns with that of the original instrument.

    Model fit indices such as χ²/df, RMSEA, CFI, TLI, and SRMR will be used to evaluate the adequacy of the factor structure.

  5. Validity Assessment- Criterion Validity

    Time frame: Through study completion, an average of 12 months

    The Turkish PROFFIT scores will be correlated with other established patient-reported outcome measures, specifically the COST (v2) and EORTC QLQ-C30 instruments, to assess convergent validity.

    Pearson or Spearman correlation coefficients will be used to determine the strength of associations between PROFFIT and these validated measures.

  6. Validity Assessment- Known-Group Validity

    Time frame: Through study completion, an average of 12 months

    To assess whether the instrument can differentiate between groups with known differences in financial toxicity, mean scores of the total and subscales will be compared across predefined demographic and clinical groups.

    Independent samples t-tests and ANOVA will be performed to compare group differences.

  7. Reliability Assessment

    Time frame: Through study completion, an average of 12 months

    Internal Consistency: The reliability of the Turkish PROFFIT instrument will be evaluated using:

    Cronbach's alpha (α) to assess the overall internal consistency of the scale. McDonald's omega (ω) as an alternative measure that provides a more robust estimation of reliability in multidimensional scales.

Study contacts

Contact information is provided by the study sponsor or research team.

Zeynep Karakuş, PhD

CONTACT

[email protected]

+902423102965

Zeynep Özer, PhD

CONTACT

Sponsors and collaborators

Lead sponsor

Akdeniz University

Other

Collaborators

  • Giresun Training and Research Hospital
  • Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale
  • St. Mary's University, Twickenham

Registry information

Official study title

Adaptation of the Patient Reported Outcomes for Fighting Financial Toxicity of Cancer (PROFFIT) Instrument Into Turkish: A Validity and Reliability Study

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jul 28, 2025
Registry last updated
Oct 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.